Veterinarians are at the heart of maintaining pet health. Pets are in the heart and soul of their owners.
Pet owners look to their veterinarian for the best recommendations when needing to treat a sick pet that they love. Whether it’s treating osteoarthritis pain, stimulating appetite or providing post-operative pain relief, veterinarians want to be at the forefront of medical innovation and have access to novel tools.
That’s why we’re committed to providing innovative therapeutics to help veterinarians raise the standard of care in veterinary medicine. We believe pets are family and they deserve high quality medical care.
ENTYCE® (capromorelin oral solution) for appetite stimulation in dogs
ENTYCE is a selective ghrelin receptor agonist that mimics the body’s naturally-occurring “hunger hormone” (ghrelin) to stimulate appetite in dogs. ENTYCE is a flavored, oral solution that is administered orally once daily. If the manufacturing transfer is approved by the FDA, Aratana believes it would be able to make ENTYCE commercially available by the fall of 2017.
NOCITA® (bupivacaine liposome injectable suspension) for local post-operative analgesia for cranial cruciate ligament surgery in dogs
NOCITA is a long-acting, local anesthetic that provides up to 72 hours post-operative pain relief by releasing bupivacaine over time from multi-vesicular liposomes. The therapeutic is administered as a single dose by tissue infiltration injection during surgical closure following cranial cruciate ligament surgery in dogs.
GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs
Galliprant is a first-in-class piprant and a non-COX-inhibiting prostaglandin receptor antagonist (PRA). It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation, and does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions.¹
In co-promotion with Elanco Animal Health, a division of Eli Lilly and Company.
IMPORTANT SAFETY INFORMATION
GALLIPRANT® (grapiprant tablets) is not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.
NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCI, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.
1. Kirkby Shaw, K., Rausch-Derra, L., and Rhodes, L. 2016. “Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation.” Vet. Med. Sci. 2: 3-9.